antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»antibiotics-11Research ArticleОБЗОРЫREVIEWSЭРАДИКАЦИЯ H.PYLORI: ОЦЕНКА РИСКА И ВОЗМОЖНОСТИ ПРОФИЛАКТИКИ МЕЖЛЕКАРСТВЕННЫХ ВЗАИМОДЕЙСТВИЙERADICATION OF H.PYLORI: RISK ASSESSMENT AND POSSIBLE PREVENTION OF DRUG-DRUG INTERACTIONSСереброваС. Ю.SerebrovaS. YU.svetaserebrova@mail.ruПрокофьевА. Б.ProkofevA. B.noemail@neicon.ruЖуравлеваМ. В.ZhuravlevaM. V.noemail@neicon.ruГородецкаяГ. И.GorodetskayaG. N.noemail@neicon.ruЕременкоН. Н.EremenkoN. N.noemail@neicon.ruСмолярчукЕ. А.SmolyarchukE. A.noemail@neicon.ruКургузоваД. О.KurguzovaD. O.noemail@neicon.ruФГБУ Научный центр экспертизы средств медицинского применения Минздрава России; ВО Первый МГМУ им. И. М. СеченоваРоссияScientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical UniversityRussian FederationВО Первый МГМУ им. И. М. СеченоваРоссияI. M. Sechenov First Moscow State Medical UniversityRussian Federation201705052020621-24451Copyright © ООО «Издательство ОКИ», 20202020ООО «Издательство ОКИ»ООО «Издательство ОКИ»https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNoticehttps://www.antibiotics-chemotherapy.ru/jour/article/view/11

Современная терапия, направленная на эрадикацию H.pylori, включает комплекс антисекреторных и антибактериальных препаратов, иногда препаратов висмута. Особенностью современных эрадикационных схем является четырнадцатидневное применение антибактериальных средств, назначаемых в высоких суточных дозах и избираемых преимущественно с учётом резистентности микроорганизма к кларитромицину и метронидазолу в соответствующем регионе. Однако каждый компонент эрадикационной схемы может иметь достаточно серьёзные неблагоприятные побочные реакции, а также влиять на биодоступность, биотрансформацию, выведение и потенцирование эффектов лекарственных препаратов, которые больной может принимать одновременно с антихеликобактерной терапией. В статье перечислены наиболее серьёзные и распространённые варианты лекарственных взаимодействий компонентов эрадикационных схем, дано описание механизма их развития, если таковой выяснен. До появления практических рекомендаций относительно профилактики лекарственных взаимодействий препаратов, включаемых в эрадикационные схемы, следует использовать общедоступные базы данных, содержащие сведения о таких взаимодействиях.

Modern therapy, aimed at eradication of H.pylori, includes a set of antisecretory and antibacterial drugs and sometimes bismuth preparations. A feature of modern eradication schemes is the 14-day use of antibiotics, prescribed in high daily doses and selected mainly based on microorganism resistance to clarithromycin and metronidazole in the respective region. However, each component of eradication scheme can have rather serious sode effects, as well as affect the bioavailability, biotransformation, excretion, and the potentiation of the effects of the drugs that the patient can take simultaneously with anti H.pylori therapy. The article lists the most serious and common variants of drug-drug interactions of the eradication schemes' components, it gives a description of the mechanism of their development, when applicable. Before the approval official of practical recommendations for the prevention of drug-drug interactions of drugs included in the eradication schemes, commonly available databases containing information about such interactions should be used.

Маастрихт Vэрадикационная терапиялекарственные взаимодействияингибиторы протонной помпыпрепараты висмутакларитромицинметронидазоллевофлоксацинрифабутинфуразолидонH.pyloriMaastricht VH.pylorieradication therapydrugs interactionsproton pump inhibitorsbismuth preparationsclarithromycinmetronidazolelevofloxacinrifabutinfurazolidoneReferencesChaput C., Ecobichon C., Cayet N., Girardin S. E., Werts C., Guadagnini S. et al. Role of AmiA in the Morphological Transition of Helicobacter pylori and in Immune Escape. PLoS Pathogens 2006; 2 (9): e97.Chaput C., Ecobichon C., Cayet N., Girardin S. E., Werts C., Guadagnini S. et al. Role of AmiA in the Morphological Transition of Helicobacter pylori and in Immune Escape. PLoS Pathogens 2006; 2 (9): e97.Johannes G. Kusters J.G., van Vliet A.H.M., Kuipers E.J. Pathogenesis of Helicobacter pylori Infection. Clinical Microbiology Reviews 2006; 19 (3): 449-490.Johannes G. Kusters J.G., van Vliet A.H.M., Kuipers E.J. Pathogenesis of Helicobacter pylori Infection. Clinical Microbiology Reviews 2006; 19 (3): 449-490.Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T.R., Bazzoli F. et al. Management of Helicobacter pylori infection the Maastricht IV/ Florence Consensus Report. The European Helicobacter Study Group. Gut 2012; 61: 646e664.Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T.R., Bazzoli F. et al. Management of Helicobacter pylori infection the Maastricht IV/ Florence Consensus Report. The European Helicobacter Study Group. Gut 2012; 61: 646e664.Borody T. J., Cole P., Noonan S., Morgan A., Lenne J., Hyland L. et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. The Medical journal of Australia 1989; 151 (8): 431-435.Borody T. J., Cole P., Noonan S., Morgan A., Lenne J., Hyland L. et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. The Medical journal of Australia 1989; 151 (8): 431-435.Malfertheiner P., Megraud F., O'Morain C.A. Gisbert J.P. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2016; 0: 1-25.Malfertheiner P., Megraud F., O'Morain C.A. Gisbert J.P. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2016; 0: 1-25.De Francesco V., Giorgio F., Hassan C., Manes G. Worldwide H.pylori Antibiotic Resistance: a Systematic. J Gastrointestin Liver Dis 2010; 19 (4): 409-414.De Francesco V., Giorgio F., Hassan C., Manes G. Worldwide H.pylori Antibiotic Resistance: a Systematic. J Gastrointestin Liver Dis 2010; 19 (4): 409-414.Smith S.M. An update on the update on the treatment of Helicobacter pylori infection. EMJ Gastroenterol 2015; 4 (1): 101-107.Smith S.M. An update on the update on the treatment of Helicobacter pylori infection. EMJ Gastroenterol 2015; 4 (1): 101-107.Li X., Andersson T.B., Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome p450 activities. Drug Metab Dispos 2004; 32 (8): 821-827.Li X., Andersson T.B., Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome p450 activities. Drug Metab Dispos 2004; 32 (8): 821-827.Goodwin M.M., Desilets A.R., Willett K.C. Thienopyridines in Acute Coronary Syndrome. The Annals of Pharmacotherapy. 2011; 45 (2): 207-217.Goodwin M.M., Desilets A.R., Willett K.C. Thienopyridines in Acute Coronary Syndrome. The Annals of Pharmacotherapy. 2011; 45 (2): 207-217.Ших E.B., Cычев А.A. Безопасность пантопразола с позиций лекарственного взаимодействия. РЖГГК 2012; 5: 4-12.Ших E.B., Cычев А.A. Безопасность пантопразола с позиций лекарственного взаимодействия. РЖГГК 2012; 5: 4-12.MOTILIUM® DATASHEET. file:///C:/Users/Admin/Desktop/Янссен%2006-12-16/Послать/motiliumtab%20(1).pdfMOTILIUM® DATASHEET. file:///C:/Users/Admin/Desktop/Янссен%2006-12-16/Послать/motiliumtab%20(1).pdfCastro V. M. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346: f288.Castro V. M. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346: f288.Lu H.R., Hermans A.N., Gallacher D.J. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? British J Pharmacol 2012; 166: 1490-1502.Lu H.R., Hermans A.N., Gallacher D.J. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? British J Pharmacol 2012; 166: 1490-1502.Davydov L., Yermolnik M., Cuni L.J. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003; 37: 367-370.Davydov L., Yermolnik M., Cuni L.J. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003; 37: 367-370.Mayor S. Short term increase in neuropsychiatric events is seen with H.pylori treatment containing clarithromycin. BMJ 2016; 353: i2481.Mayor S. Short term increase in neuropsychiatric events is seen with H.pylori treatment containing clarithromycin. BMJ 2016; 353: i2481.Visser L.E., Penning-Van Bees F.J., Harrie Kasbergen A.A. et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002 (88): 705-710.Visser L.E., Penning-Van Bees F.J., Harrie Kasbergen A.A. et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002 (88): 705-710.Otsuka S.H. Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction. Pharmacotherapy 2013 (33): e45-49.Otsuka S.H. Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction. Pharmacotherapy 2013 (33): e45-49.Lipsky B.A., Baker C.A. Fluoroquinolone Toxicity Profiles: A Review Focusing on Newer Agents. Clin Infect Dis 1999; 28: 352-364.Lipsky B.A., Baker C.A. Fluoroquinolone Toxicity Profiles: A Review Focusing on Newer Agents. Clin Infect Dis 1999; 28: 352-364.American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. AGS 2015 Beers Criteria update expert panel. JAGS 2015; 63 (11): 2227-2246.American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. AGS 2015 Beers Criteria update expert panel. JAGS 2015; 63 (11): 2227-2246.

The authors declare that there are no conflicts of interest present.